Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $64
PTC Therapeutics Analyst Ratings
Baird Initiates Coverage On PTC Therapeutics With Outperform Rating, Announces Price Target of $44
Baird Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $44
PTC Therapeutics Price Target Announced at $47.00/Share by UBS
PTC Therapeutics Analyst Ratings
UBS Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $47
Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target
PTC Therapeutics Analyst Ratings
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $37
PTC Therapeutics Analyst Ratings
Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $31
PTC Therapeutics: Sell Rating Due to DMD Franchise Challenges and Pipeline Uncertainties
Buy Rating Affirmed for PTC Therapeutics on Strong Q2 Performance and Promising Pipeline
Analysts Conflicted on These Healthcare Names: Cytokinetics (CYTK), Doximity (DOCS) and PTC Therapeutics (PTCT)
Barclays Sticks to Their Hold Rating for PTC Therapeutics (PTCT)
Maintained Sell Rating for PTC Therapeutics Amidst Sales Shortfall and Regulatory Hurdles
Leerink Partners Reaffirms Their Hold Rating on PTC Therapeutics (PTCT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)